Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), sequela

• birth trauma (P10-P15)
• obstetric trauma (O70-O71)

code to identify any retained foreign body, if applicable (Z18.-)

• Use secondary code(s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code
• The chapter uses the S-section for coding different types of injuries related to single body regions and the T-section to cover injuries to unspecified body regions as well as poisoning and certain other consequences of external causes.

• adverse effect of correct substance properly administered
• poisoning by overdose of substance
• poisoning by wrong substance given or taken in error
• underdosing by (inadvertently) (deliberately) taking less substance than prescribed or instructed

toxic reaction to local anesthesia in pregnancy (O29.3-)

• abuse and dependence of psychoactive substances (F10-F19)
• abuse of non-dependence-producing substances (F55.-)
• immunodeficiency due to drugs (D84.821)
• drug reaction and poisoning affecting newborn (P00-P96)
• pathological drug intoxication (inebriation) (F10-F19)

• , for adverse effects, the nature of the adverse effect, such as:
• adverse effect NOS (T88.7)
• aspirin gastritis (K29.-)
• blood disorders (D56-D76)
• contact dermatitis (L23-L25)
• dermatitis due to substances taken internally (L27.-)
• nephropathy (N14.0-N14.2)

• code(s) to specify:
• manifestations of poisoning
• underdosing or failure in dosage during medical and surgical care (Y63.6, Y63.8-Y63.9)
• underdosing of medication regimen (Z91.12-, Z91.13-)

The drug giving rise to the adverse effect should be identified by use of codes from categories T36-T50 with fifth or sixth character 5.

The appropriate 7th character is to be added to each code from category T45

poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drug (T45.1)

Poisoning by immune checkpoint inhibitors and immunosuppressive drugs NOS